Browse TSSK2

Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole Note=Present in the cytoplasm of elongating spermatids. In spermatozoa, localizes in the equatorial segment, neck, the midpiece and in a specific sperm head compartment (By similarity). In spermatids, concentrates in centrioles during flagellogenesis.
Domain PF00069 Protein kinase domain
Function

Testis-specific serine/threonine-protein kinase required during spermatid development. Phosphorylates TSKS at 'Ser-288' and SPAG16. Involved in the late stages of spermatogenesis, during the reconstruction of the cytoplasm. During spermatogenesis, required for the transformation of a ring-shaped structure around the base of the flagellum originating from the chromatoid body.

> Gene Ontology
 
Biological Process GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007286 spermatid development
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0046777 protein autophosphorylation
GO:0048232 male gamete generation
GO:0048515 spermatid differentiation
Molecular Function GO:0000287 magnesium ion binding
GO:0004674 protein serine/threonine kinase activity
Cellular Component GO:0001669 acrosomal vesicle
GO:0005813 centrosome
GO:0005814 centriole
GO:0030141 secretory granule
GO:0044450 microtubule organizing center part
GO:0097223 sperm part
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TSSK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TSSK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TSSK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9870.223
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3090.824
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.8560.314
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4270.375
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4270.541
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1180.414
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TSSK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TSSK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TSSK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TSSK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TSSK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TSSK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TSSK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTSSK2
Nametestis-specific serine kinase 2
Aliases SPOGA2; FLJ38613; STK22B; serine/threonine kinase 22B (spermiogenesis associated); DGS-G; TSK2; TSK-2; TSSK- ......
Chromosomal Location22q11.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TSSK2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.